SVRA
Savara Inc.
$4.52
+0.30
(+7.11%)
Mkt Cap
890.40M
Volume
3,441,276
52W Range
3.86-7.01
Sector
Healthcare
Beta
0.25
EPS (TTM)
-0.58 USD
P/E Ratio
-11.38
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 257,000 | 0 | 0 | 0 | 400,000 | 54 | 1,548 |
| Net Income | (118.84M) | (95.88M) | (54.70M) | (38.15M) | (43.01M) | (49.62M) | (78.17M) | (61.52M) | (29.80M) | (10.92M) | (39.84M) | (28.70M) |
| EPS | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 |
| Free Cash Flow | (101.06M) | (89.11M) | (51.36M) | (34.56M) | (40.14M) | (43.13M) | (45.27M) | (39.42M) | (28.73M) | (8.38M) | (33.11M) | (24.79M) |
| FCF / Share | -0.45 | -0.45 | -0.31 | -0.23 | -0.30 | -0.73 | -1.13 | -1.18 | -1.64 | -2.50 | -14.29 | -14.18 |
| Operating CF | (101.04M) | (89.09M) | (51.06M) | (34.55M) | (40.08M) | (39.84M) | (45.12M) | (39.27M) | (28.23M) | (8.37M) | (32.95M) | (24.64M) |
| Total Assets | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M | 97.75M | 136.20M | 152.29M | 159.63M | 28.93M | 54.22M | 70.50M |
| Total Debt | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M | 25.28M | 25.55M | 24.57M | 15.34M | 4.47M | 14.74M | 0 |
| Cash & Equiv | 33.18M | 15.13M | 26.59M | 52.10M | 34.01M | 22.88M | 49.80M | 24.30M | 22.12M | 13.37M | 23.05M | 35.81M |
| Book Value | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M | 64.38M | 101.70M | 108.22M | 119.31M | (35.88M) | 23.89M | 58.66M |
| Return on Equity | -0.59 | -0.56 | -0.39 | -0.35 | -0.30 | -0.77 | -0.77 | -0.57 | -0.25 | N/A | -1.67 | -0.49 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (40.23M) | (37.28M) | (32.24M) | (29.56M) | (30.40M) | (26.64M) | (29.04M) | (24.25M) | (22.24M) | (20.35M) | (16.10M) | (16.60M) |
| EPS | -0.16 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.14 | -0.11 | -0.12 | -0.11 | -0.09 | -0.10 |
| Free Cash Flow | (29.97M) | (33.10M) | (25.06M) | (22.53M) | (26.28M) | (27.19M) | (23.27M) | (22.67M) | (22.52M) | (20.65M) | (15.63M) | (13.20M) |
| FCF / Share | -0.12 | -0.13 | -0.11 | -0.10 | -0.12 | -0.13 | -0.12 | -0.11 | -0.12 | -0.11 | -0.09 | -0.08 |
| Operating CF | (29.75M) | (33.05M) | (25.06M) | (22.53M) | (26.26M) | (27.19M) | (23.28M) | (22.67M) | (22.50M) | (20.64M) | (15.60M) | (13.16M) |
| Total Assets | 192.14M | 221.65M | 253.44M | 140.92M | 163.76M | 189.32M | 212.88M | 238.82M | 139.67M | 158.29M | 177.56M | 182.07M |
| Total Debt | 30.11M | 30.11M | 29.91M | 29.83M | 29.74M | 29.64M | 26.73M | 26.71M | 26.64M | 26.56M | 26.49M | 26.70M |
| Cash & Equiv | 41.80M | 38.79M | 33.18M | 16.28M | 17.44M | 19.56M | 15.13M | 21.43M | 23.86M | 16.79M | 26.59M | 27.69M |
| Book Value | 143.66M | 176.04M | 203.13M | 94.39M | 120.48M | 147.85M | 171.45M | 199.35M | 101.73M | 121.86M | 140.37M | 146.54M |
| Return on Equity | -0.28 | -0.21 | -0.16 | -0.31 | -0.25 | -0.18 | -0.17 | -0.12 | -0.22 | -0.17 | -0.11 | -0.11 |
SVRA News
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Announces New Employment Inducement Grant
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump